Non-Steroidal anti-inflammatory drug-associated ulcers

  • C. J. Hawkey
Chapter
Part of the Milestones in Drug Therapy MDT book series (MDT)

Abstract

The gastrointestinal side effects of nonsteroidal anti-inflammatory drugs, particularly with the development of ulcer bleeding and perforation, probably represent the most important iatrogenic problem in the developed world. Acute mucosal injury is almost universal after consumption of single doses of aspirin [1] and, although acute injury is a little slower to develop with nonaspirin non-steroidal anti-inflammatory drugs (NSAIDs), the prevalence of ulcers in patients taking NSAIDs or anti-inflammatory doses of aspirin has been shown to be around 20% [2]. In many cases these ulcers remain silent and cause no clinical harm, but a minority result in the ulcer complications of bleeding and perforation at a rate somewhere between 1 in 50 and 1 in 100 patient years [3]. As a result, it is likely that at least 1200 patients per annum in the United Kingdom die as a result of NSAID-associated ulcer complications [4]. Whilst it is important to stress that NSAIDs, particularly aspirin, have additional benefits in terms of protection against cardiovascular disease [5] and cancer [6] which almost certainly more than outweigh these risks, any strategy which could reduce NSAID-associated ulcer disease and complications is welcome.

Keywords

Peptic Ulcer Duodenal Ulcer Gastric Ulcer Pylorus Eradication Dyspeptic Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hawkey CJ, Hawthorne AB, Hudson N, Cole AT, Mahida YR, Daneshmend TK (1991) Separation of aspirin’s impairment of haemostasis from mucosal injury in the human stomach. Clin Sci 81: 565–573PubMedGoogle Scholar
  2. 2.
    Hawkey CJ, Hudson N (1994) Mucosal injury caused by drugs, chemicals and stress. In: WS Haubrich, F Schaffner, JE Berk, WB Saunders (eds): Bockus gastroenterology, 5th edn. Saunders, vol 2, 656–699Google Scholar
  3. 3.
    Silverstein FE, Graham DY, Senior JR et al (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal antiinflammatory drugs. A randomised, double blind, placebo controlled trial. Ann Intern Med 123:241–249PubMedGoogle Scholar
  4. 4.
    Hawkey CJ (1990) Non-steroidal anti-inflammatory drugs and ulcers: facts and figures multiple, but do they add up? Br Med J 300: 278–284CrossRefGoogle Scholar
  5. 5.
    Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-III: reduction of venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Brit Med J 308: 235–246CrossRefGoogle Scholar
  6. 6.
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327PubMedGoogle Scholar
  7. 7.
    Hawkey CJ, Rampton DS (1985) Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease or treatment? Gastroenterology 89: 1161–1189Google Scholar
  8. 8.
    Whittle BJR (1981) Temporal relationship between cyclooxygenase inhibition as measured by prostacyclin biosynthesis and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 80: 94–98PubMedGoogle Scholar
  9. 9.
    Elliott SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND (1996) Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exper Pharmacol Physiol 23: 432–434CrossRefGoogle Scholar
  10. 10.
    Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ (1990) Abolition by omeprazole of aspirin-induced gastric mucosal injury in man. Gut 31: 514–517PubMedCrossRefGoogle Scholar
  11. 11.
    Walt RP (1992) Misoprostol for the treatment of peptic ulcer and anti-inflammatory drug-induced gastroduodenal ulceration. New Engl J Med 327: 1575–1580PubMedCrossRefGoogle Scholar
  12. 12.
    Hogben CAM, Schanker LS, Tocco DJ, Brodie BB (1957) Absorption of drugs from the stomach II. Hum J Pharmacol Exp Ther 120: 540–545Google Scholar
  13. 13.
    Cvasta TE, Cooke AR (1972) The effect of several ulcerogenic drugs on the canine gastric barrier. J Lab Clin Med 79: 302–308Google Scholar
  14. 14.
    Samloff IM (1971) pepsinogens, pepsins and pepsin inhibitors. Gastroenterology 586-604Google Scholar
  15. 15.
    Konturek SJ, Brzozowski T, Radecki T (1983) Protective action of omeprazole, a benzimidazole derivative, on gastric mucosal damage by aspirin and ethanol in rats. Digestion 27(3): 159–164PubMedCrossRefGoogle Scholar
  16. 16.
    Okabe S, Miyake H, Awane Y (1986) Cytoprotective effects of NC-1300 and omeprazole on HC1 ethanol-induced gastric lesions in rats. Japanese J Pharmacol 42(1): 123–133CrossRefGoogle Scholar
  17. 17.
    Romano M, Razandi M, Ivey KJ (1989) Protection of gastric epithelial cell monolayers from a human cell line by omeprazole in vitro. Scand J Gastroenterol 24(5): 513–521PubMedCrossRefGoogle Scholar
  18. 18.
    O’Brien PE, Frydman G, Holmes R, Malcontenti C, Phelan D (1990) Evaluation of putative cytoprotective of anti-ulcer drugs using quantitative histological techniques. Dig Dis Sci 35(9): 1130–1139PubMedCrossRefGoogle Scholar
  19. 19.
    Blandizzi C, Gherardi G, Marveggio C, Natale G, Carignani D, Del Tacca M (1995) Mechanisms of protection of omeprazole against experimental gastric mucosal damage in rats. Digestion 56(3): 220–229PubMedCrossRefGoogle Scholar
  20. 20.
    Ichikawa T, Ishihara K, Saigenji K, Hotta K (1991) Effects of omeprazole on gastric mucus glycoprotein biosynthesis. Gastroenterologia Japonica 26(3): 390PubMedGoogle Scholar
  21. 21.
    Parodi MC, Cognein P, Fazzuoli L, Sacco T (1992) Effects of omeprazole on gastric mucus secretion, tissue prostaglandin synthesis, and acid inhibition in patients with duodenal ulcer: comparison with ranitidine treatment. Current Therapeutic Research, Clinical Experimental 52(1): 13–23CrossRefGoogle Scholar
  22. 22.
    Guslandi M, Franceschi M, Fanti L, Pellegrini A, Tittobello A (1992) Omeprazole-induced changes in gastric mucus secretion. Methods Find Exp Clin Pharmacol 13(3): 219–223Google Scholar
  23. 23.
    Mizuguchi Y, Kawai T, Miwa K, Takei K, Mizumura Y, Sanada J, Niki S, Takeda K, Onoda K, Shinohara Y et al (1996) The effects of a proton pump inhibitor (omeprazole) on amounts of gastric mucus and gastric mucosal proliferation in rats. J Tokyo Med Coll 54(5): 460–470Google Scholar
  24. 24.
    Ohara S, Murayama N, Kuwata H, Ishihara K, Hotta K (1988) Effects of omeprazole on rat gastric mucus glycoproteins with acetylsalicylic acid-induced gastric damage. Arch Int Pharmacodynam Ther 296: 92–201Google Scholar
  25. 25.
    Bigard MA, Isal JP (1988) Complete prevention by omeprazole of aspirin induced gastric lesions in healthy subjects. Gut 29: A712Google Scholar
  26. 26.
    Scheiman JM, Belcher EM, Loeffler KM, Elta GH (1994) Omeprazole ameliorates aspirininduced gastroduodenal injury. Dig Dis Sci 39: 97–103PubMedCrossRefGoogle Scholar
  27. 27.
    Simon B, Eisner H, Muller P (1995) Protective effects of omeprazole against low-dose acetylsalicyl acid. An endoscopie controlled double-blind study in healthy volunteers. Arzneimittelforschung 45(6): 701–703PubMedGoogle Scholar
  28. 28.
    Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, Mann SG, Simon TJ, Sturrock RD, Russell RI (1996) Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. New EnglJ Med 334: 1435–1439CrossRefGoogle Scholar
  29. 29.
    Hudson N, Taha AS, Russell RI, Sturrock RG, Trye P, Cottrell J, Mann SG, Swannell AJ, Hawkey CJ (1997) Famotidine for healing and maintenance in non-steroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 112(6): 1817–1822PubMedCrossRefGoogle Scholar
  30. 30.
    Hawkey CJ, Karrasch IA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans Nd (1998) Omeprazole compared with misoprostol for treating and preventing ulcers associated with nonsteroidal antiinflammatory drugs. New EnglJ Med 338(11): 727–734CrossRefGoogle Scholar
  31. 31.
    Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ (1998) A comparison of omeprazole and ranitidine for treating and preventing ulcers associated with nonsteroidal antiinflammatory drugs. New Engl J Med 338(11): 719–726PubMedCrossRefGoogle Scholar
  32. 32.
    Ekström P, Carling L, Wetterhus S et al (1996) Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal antiinflammatory drug therapy — A Nordic Multicentre Study. Scand J Gastroenterol 31: 753–758PubMedCrossRefGoogle Scholar
  33. 33.
    Cullen D, Bardhan KD, Eisner M, Kogut M, Peacock RA, Thomson JM, Hawkey CJ (1998) Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 2: 135–140.CrossRefGoogle Scholar
  34. 34.
    Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, Wason CM, Peacock RA, Gillon KRW (1998) Helicobacterpylori eradication in patients taking non-steroidal, anti-inflammatory drugs: the HELP NSAIDS study. Lancet 352: 1016–1021.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 1999

Authors and Affiliations

  • C. J. Hawkey
    • 1
  1. 1.Department of Medicine, Division of GastroenterologyUniversity Hospital, Queen’s Medical CentreNottinghamUK

Personalised recommendations